Stockscreener 앱 받기
1.83
28.87%
0.41
시간 외 거래:
1.84
0.01
+0.55%
전일 마감가:
$1.42
열려 있는:
$1.39
하루 거래량:
11.83M
Relative Volume:
5.08
시가총액:
$110.13M
수익:
-
순이익/손실:
$-33.85M
주가수익비율:
-3.2458
EPS:
-0.5638
순현금흐름:
$-33.35M
1주 성능:
-60.81%
1개월 성능:
-63.98%
6개월 성능:
-62.88%
1년 성능:
-72.19%
1일 변동 폭
$1.37
$1.85
1주일 범위
$1.07
$4.72
52주 변동 폭
$1.07
$6.87
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.83 | 85.46M | 0 | -33.85M | -33.35M | -0.5638 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
What's Going On With Aldeyra Therapeutics Stock On Thursday? - Benzinga
BTIG Maintains Buy on Aldeyra Therapeutics, Inc. (ALDX) March 2026 - Meyka
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky - PR Newswire
Does Aldeyra Therapeutics (ALDX) have the potential to rally 79.28% as Wall Street analysts expect? - MSN
HC Wainwright & Co. downgrades Aldeyra Therapeutics (ALDX) - MSN
Aldeyra’s CEO to Lead Strategic Discussions at Healthcare Conference - StocksToTrade
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) - The Globe and Mail
Aldeyra Eyes Growth as CEO Prepares for Key Conference - timothysykes.com
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Aldeyra Therapeutics, Inc. - 富途牛牛
ALDX Plummets 71% Following FDA's Third Complete Response Letter for Dry Eye Disease Drug Application - Bitget
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA - Yahoo Finance
Upcoming Conference Sheds Light on Aldeyra Therapeutics’ Innovations - StocksToTrade
Aldeyra shares plunge after third FDA rejection for reproxalap - The Pharma Letter
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ALDX Stock Downgraded by HC Wainwright & Co. with Price Target R - GuruFocus
H.C. Wainwright cuts Aldeyra stock rating on FDA setback - Investing.com
Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection - Yahoo Finance
HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10 - marketscreener.com
FDA issues CRL to Aldeyra’s reproxalap drug application - Yahoo Finance
Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy DataHas The Bull Case Changed? - simplywall.st
FDA rejects Aldeyra’s dry eye disease drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalap - geneonline.com
Aldeyra Therapeutics (ALDX) Faces Major Setback as FDA Rejects E - GuruFocus
Aldeyra Therapeutics stock plunges 70% after third FDA rejection - The Business Journals
Aldeyra Therapeutics stock maintained at Buy by BTIG after FDA setback - Investing.com
US FDA declines to approve Aldeyra’s eye disorder drug, shares slump - WSAU
Third Time Is Not The Charm For Aldeyra - Citeline News & Insights
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton ... - Bluefield Daily Telegraph
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For - GlobeNewswire
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm - GlobeNewswire Inc.
FDA rejects Aldeyra's dry eye drug for third time, stock crashes 68% - MSN
Aldeyra plunges as FDA rejects dry eye disease therapy - MSN
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lacking Evidence, FDA Rejects Aldeyra Dry Eye Disease Drug - MedCity News
Why Aldeyra Therapeutics Stock Just Hit 52-Week LowAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Aldeyra Therapeutics Sees Unusually High Options Volume (NASDAQ:ALDX) - MarketBeat
Aldeyra collects third CRL for reproxalap in dry eye disease - BioWorld MedTech
FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings - Fierce Biotech
Aldeyra Therapeutics Shares Plummet Amid Financial Concerns - StocksToTrade
Aldeyra Therapeutics Receives FDA Complete Response Letter for Reproxalap Dry Eye Disease Treatment, No Additional Trials Required 1 - Minichart
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - marketscreener.com
Aldeyra Therapeutics Shareholders Are Encouraged to Reach - GlobeNewswire
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting - BioSpace
Aldeyra Therapeutics (ALDX) Faces FDA Rejection for Dry Eye Drug - GuruFocus
Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings - Benzinga
Aldeyra Therapeutics Sees Stock Movement Amid Latest Developments - timothysykes.com
US FDA declines to approve Aldeyra’s drug for eye disorder - KFGO
Aldeyra receives third complete response letter for reproxalap - Ophthalmology Times
FDA rejects Aldeyra’s dry eye disease drug application - Investing.com
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):